Celldex Therapeutics Announces Upcoming Data Presentations at the Society for Immunotherapy of Cancer and Society of Neuro

Celldex Therapeutics Announces Upcoming Data Presentations at the Society for
Immunotherapy of Cancer and Society of Neuro-Oncology Annual Meetings

PHILLIPSBURG, N.J., Oct. 21, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics,
Inc. (Nasdaq:CLDX) announced today that data from two of its clinical
programs, the Phase 1 dose-escalation CDX-1127 study and the Phase 2 recurrent
rindopepimut study, will be presented at two upcoming medical meetings, the
Society for Immunotherapy of Cancer (SITC) and the Society of Neuro-Oncology
(SNO), respectively. The Company also announced its communication plan around
these data presentations.

SITC, November 7-10, National Harbor, Maryland

The embargo for all data to be presented at SITC lifts on Thursday, November 7
at 8:00 am ET, at which time abstracts will be published on the SITC website.
Celldex has three abstracts on CDX-1127 that have been accepted for poster
presentation (outlined below). Concurrent with the embargo lifting, Celldex
will issue a press release that will include the preliminary data contained in
the abstracts and updated data that will be presented in the poster sessions.
Management will also hold a conference call at 8:30 am ET on Thursday,
November 7 to review the data.

  *Data from the solid tumor arm of the Phase 1 dose-escalation study of
    CDX-1127 will be presented in a poster session entitled "A Phase 1 Study
    of an Agonist anti-CD27 Human Antibody (CDX-1127) in Patients with
    Advanced Hematologic Malignancies or Solid Tumors" on Saturday, November 9
    from 1:00 pm to 2:00 pm and 6:15 pm to 7:15 pm ET.
    
  *Data from the hematologic arm of the Phase 1 dose-escalation study of
    CDX-1127 will be presented in a poster session entitled "A Phase 1 Study
    of an Agonist anti-CD27 Human Antibody (CDX-1127) in Patients with
    Advanced Hematologic Malignancies or Solid Tumors" on Saturday, November 9
    from 1:00 pm to 2:00 pm and 6:15 pm to 7:15 pm ET.
    
  *Data from preclinical combination studies of CDX-1127 with chemotherapies
    and checkpoint inhibitors will be presented in a poster session entitled
    "Combination Therapies Augment the Anti-tumor Activity of Agonist CD27 mAb
    in Human CD27 Transgenic Mouse Models" on Friday, November 8 from 1:00 pm
    to 2:00 pm and 6:15 pm to 7:15 pm ET.

SNO, November 21-24, San Francisco, California

The embargo for abstracts lifts on Monday, November 11 at 7:00 am ET, at which
time the abstracts will be published on the SNO website. Preliminary data from
the ReACT study will be included in an abstract accepted for an oral
presentation entitled "ReACT: a Phase 2 Study of Rindopepimut Vaccine
(CDX-110) Plus Bevacizumab in Relapsed Glioblastoma." Celldex will present a
more expansive, updated data package from the ReACT study in this oral
session, which is scheduled for Sunday, November 24 from 10:20 am to 12:00 pm
PT. The Company will issue a press release in concordance with this
presentation. On Monday, November 25 at 8:30 am ET, management will also hold
a conference call to review the data.

About Celldex Therapeutics, Inc.:

Celldex is developing targeted therapeutics to address devastating diseases
for which available treatments are inadequate. Our pipeline is built from a
proprietary portfolio of antibodies and immunomodulators used alone and in
strategic combinations to create novel, disease-specific therapies that
induce, enhance or suppress the body's immune response. Visit
www.celldextherapeutics.com.

CONTACT: Company Contact:
         Sarah Cavanaugh
         Vice President of IR & Corp Comm
         Celldex Therapeutics, Inc.
         (781) 433-3161
         scavanaugh@celldextherapeutics.com
 
Press spacebar to pause and continue. Press esc to stop.